{"protocolSection":{"identificationModule":{"nctId":"NCT04913831","orgStudyIdInfo":{"id":"4-2021-0085"},"organization":{"fullName":"Yonsei University","class":"OTHER"},"briefTitle":"Effects of Cerebrolysin on Level of Consciousness and Brain Metabolism in Disorder of Consciousness After Stroke: Single Center Randomized Controlled Study","officialTitle":"Effects of Cerebrolysin on Level of Consciousness and Brain Metabolism in Disorder of Consciousness After Stroke: Single Center Randomized Controlled Study"},"statusModule":{"statusVerifiedDate":"2021-05","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2021-06","type":"ESTIMATED"},"primaryCompletionDateStruct":{"date":"2024-03","type":"ESTIMATED"},"completionDateStruct":{"date":"2024-03","type":"ESTIMATED"},"studyFirstSubmitDate":"2021-05-25","studyFirstSubmitQcDate":"2021-05-26","studyFirstPostDateStruct":{"date":"2021-06-04","type":"ACTUAL"},"lastUpdateSubmitDate":"2021-05-26","lastUpdatePostDateStruct":{"date":"2021-06-04","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Yonsei University","class":"OTHER"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The purpose of this study was to determine the effect of stroke on post-stroke level of consciousness through a double-blind, placebo-controlled, randomized study design. And Brain 18F-FDG PET was used to reveal the mechanism of recovery after cerebrolysin administration.\n\nThirty patients with chronic stroke patients with minimal consciousness (MCS) or vegetative human (VS) level of consciousness disorder in the revised coma recovery scale were enrolled. Thirty patients were randomly divided into a Cerebrolysin group and a placebo group."},"conditionsModule":{"conditions":["Stroke"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE4"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":30,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Cerebrolysin","type":"EXPERIMENTAL","interventionNames":["Drug: Cerebrolysin"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"type":"DRUG","name":"Cerebrolysin","description":"Cerebrolysin 20ml + physiological saline 80ml, 8-35 days, once/day, intravenous administration","armGroupLabels":["Cerebrolysin"]},{"type":"DRUG","name":"Placebo","description":"physiological saline 100ml, 8-35 days, once/day, intravenous administration","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"CRS-R (JFK Coma recovery scale-revised)","description":"It is a test that analyzes a total of six functions of hearing, vision, movement, speech, communication, and arousal by item to determine the improvement in the level of consciousness of patients with decreased consciousness. These items are scored to determine whether they are in a minimally conscious state (MCS).","timeFrame":"up to 11 weeks"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Ischemic or hemorrhagic stroke patients\n* Stroke with CT or MRI diagnosis\n* Chronic patients with more than 3 months of stroke onset\n* Patients with vegetative status or minimal consciousness (Coma Recovery Scale -revised: CRS-R)\n* Age: 19 to 90 years old\n* A person who voluntarily consents to the clinical trial in writing by the principal or legal representative\n\nExclusion Criteria:\n\n* In case of contraindications, including allergies to cerebrolysin\n* Patients with contraindications to PET\n* Progressive or unstable stroke\n* In case of accompanying serious neurogenic disease\n* Major depressive disorder, schizophrenia, bipolar disorder, dementia, and other serious psychiatric diseases.\n* History of alcohol or other drug addiction within 3 years of onset\n* In case of accompanying serious liver, kidney, heart, or respiratory disease\n* If you have the following medical abnormalities (Total serum bilirubin\\> 4 mg/dL, alkaline phosphatase\\> 250 U/L, SGOT/AST\\> 150 U/L, SGPT/ALT\\> 150 U/L, or creatinine) \\> 3.5 mg/dL)\n* In case of having a medical disease that is less than 1 year old\n* During pregnancy or lactation\n* Participating in other therapeutic research","healthyVolunteers":false,"sex":"ALL","minimumAge":"19 Years","maximumAge":"90 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Deog Young Kim","role":"CONTACT","phone":"82-2-2228-3714","email":"KIMDY@yuhs.ac"}],"overallOfficials":[{"name":"Deog Young Kim","affiliation":"Department and Research Institute of Rehabilitation Medicine, Yonsei University College of Medicine, Seoul, Yonsei University College of Medicine","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Yonsei University Health System, Severance Hospital","status":"RECRUITING","city":"Seoul","country":"Korea, Republic of","contacts":[{"name":"Deog Young Kim","role":"CONTACT","phone":"82-2-2228-3714","email":"KIMDY@yuhs.ac"}],"geoPoint":{"lat":37.566,"lon":126.9784}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000003244","term":"Consciousness Disorders"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000019954","term":"Neurobehavioral Manifestations"},{"id":"D000009461","term":"Neurologic Manifestations"},{"id":"D000019965","term":"Neurocognitive Disorders"},{"id":"D000001523","term":"Mental Disorders"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M6158","name":"Consciousness Disorders","asFound":"Disorders of Consciousness","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M21516","name":"Neurobehavioral Manifestations","relevance":"LOW"},{"id":"M12094","name":"Neurologic Manifestations","relevance":"LOW"},{"id":"M21526","name":"Neurocognitive Disorders","relevance":"LOW"},{"id":"M4505","name":"Mental Disorders","relevance":"LOW"},{"id":"M14163","name":"Psychotic Disorders","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"BXM","name":"Behaviors and Mental Disorders"}]},"interventionBrowseModule":{"meshes":[{"id":"C000006952","term":"Cerebrolysin"}],"ancestors":[{"id":"D000018696","term":"Neuroprotective Agents"},{"id":"D000020011","term":"Protective Agents"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000018697","term":"Nootropic Agents"}],"browseLeaves":[{"id":"M351658","name":"Cerebrolysin","asFound":"VII","relevance":"HIGH"},{"id":"M20463","name":"Neuroprotective Agents","relevance":"LOW"},{"id":"M21559","name":"Protective Agents","relevance":"LOW"},{"id":"M20464","name":"Nootropic Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"NeuroAg","name":"Neuroprotective Agents"},{"abbrev":"NootAg","name":"Nootropic Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}